Health ❯Healthcare ❯Patient Safety

Drug Side Effects

Clinical Research Hospital Admissions Psychiatric Disorders Brain Swelling Post-Marketing Surveillance Pregnancy Outcomes Gastrointestinal Issues

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock

The experimental drug combines GLP-1 and amylin hormones, offering potential advances in obesity treatment.

Growing Demand for Weight-Loss Drugs in the UK Raises Safety and Accessibility Concerns